While most people believe COVID-19 vaccines are safe and their side effects are now clear, a new HarrisX poll conducted for the Deseret News finds a big partisan difference in how people view COVID-19 vaccine safety and effectiveness.
A vaccine from Pfizer showed the potential to protect adults ages 18 to 59 who are at increased risk of getting severely sick from respiratory syncytial virus in a late stage clinical trial, the company said Tuesday.
Despite vaccine shortages, many younger people in New York City accessed vaccines ahead of schedule, particularly in high-income areas, according to new research at Columbia University Mailman School of Public Health.
Low-income areas with high proportions of older people demonstrated lower coverage rates than wealthier areas in the first three months of vaccine rollout, and higher mortality over the year. The findings are published in the Journal of Urban Health.